India to United Arab Emirates: Cyclophosphamide Export Trade Route

The India to United Arab Emirates Cyclophosphamide corridor is one of India's established pharmaceutical export routes, with 115 shipments documented worth a combined $230.4K USD. The route is dominated by VAMA LIFECARE PRIVATE LIMITED, which alone accounts for roughly 88% of all export value, reflecting the consolidated nature of India's cyclophosphamide manufacturing sector.

Across 37 active suppliers, the average shipment value stands at $2.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 72% of all shipments, consistent with cyclophosphamide's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 23 days port-to-port. The route has recorded an annual growth rate of 29.5%, placing it at rank #13 among India's top cyclophosphamide export destinations globally.

On the import side, key buyers of Indian cyclophosphamide in United Arab Emirates include TO THE, TO THE MANAGER, TO THE ORDER OF INVOICE and 35 others. TO THE is the single largest importer with 5 shipments valued at $201.9K USD.

India's cyclophosphamide exports to United Arab Emirates are driven primarily by a handful of large-scale manufacturers. VAMA LIFECARE PRIVATE LIMITED with 6 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 37 active exporters signals a competitive but concentrated market — buyers in United Arab Emirates benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — VAMA LIFECARE PRIVATE LIMITED, GOLDFIELD HEALTHCARE, RMPL PHARMA LLP — together account for 91% of total trade value on this route. The average shipment value of $2.0K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as harmless medicine for human consumptioninj cyclophosphamide 500 mg usp batch no23acp01 mfg dt jan 23 exp dt dec 24 and harmless medicine for human consumptioninj cyclophosphamide 500 mg usp batch no23bcp02 mfg dt feb 23 exp dt jan 25, suggesting that buyers in United Arab Emirates tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, TO THE is the largest importer with 5 shipments worth $201.9K USD — representing 88% of all cyclophosphamide imports from India on this route. A total of 38 buyers are active on this corridor.